Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Total Non-Current Liabilities (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $103.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 0.95% year-over-year to $103.1 million, compared with a TTM value of $103.1 million through Dec 2025, down 0.95%, and an annual FY2025 reading of $103.1 million, down 0.95% over the prior year.
  • Total Non-Current Liabilities was $103.1 million for Q4 2025 at Treace Medical Concepts, down from $107.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $116.2 million in Q1 2024 and bottomed at $37.9 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $88.7 million, with a median of $100.0 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities surged 135.35% in 2022, then decreased 13.62% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $47.6 million in 2021, then skyrocketed by 107.03% to $98.5 million in 2022, then grew by 15.66% to $113.9 million in 2023, then dropped by 8.61% to $104.1 million in 2024, then dropped by 0.95% to $103.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for TMCI at $103.1 million in Q4 2025, $107.2 million in Q3 2025, and $108.8 million in Q2 2025.